- Home
- CSGP vs ONC Comparison
CSGP vs ONC Comparison
Compare CSGP & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSGP
- ONC
- Stock Information
- Founded
- CSGP 1987
- ONC 2010
- Country
- CSGP United States
- ONC Switzerland
- Employees
- CSGP N/A
- ONC N/A
- Industry
- CSGP Business Services
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- CSGP Consumer Discretionary
- ONC Health Care
- Exchange
- CSGP Nasdaq
- ONC Nasdaq
- Market Cap
- CSGP 32.1B
- ONC 26.9B
- IPO Year
- CSGP 1998
- ONC N/A
- Fundamental
- Price
- CSGP $73.27
- ONC $245.93
- Analyst Decision
- CSGP Buy
- ONC Strong Buy
- Analyst Count
- CSGP 14
- ONC 7
- Target Price
- CSGP $88.43
- ONC $326.43
- AVG Volume (30 Days)
- CSGP 2.7M
- ONC 364.6K
- Earning Date
- CSGP 07-22-2025
- ONC 05-07-2025
- Dividend Yield
- CSGP N/A
- ONC N/A
- EPS Growth
- CSGP N/A
- ONC N/A
- EPS
- CSGP 0.28
- ONC N/A
- Revenue
- CSGP $2,812,000,000.00
- ONC $4,180,740,829.00
- Revenue This Year
- CSGP $16.88
- ONC $32.78
- Revenue Next Year
- CSGP $12.38
- ONC $19.07
- P/E Ratio
- CSGP $262.45
- ONC N/A
- Revenue Growth
- CSGP 11.28
- ONC 52.09
- 52 Week Low
- CSGP $68.26
- ONC $141.31
- 52 Week High
- CSGP $83.68
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- CSGP 39.88
- ONC N/A
- Support Level
- CSGP $73.25
- ONC N/A
- Resistance Level
- CSGP $75.25
- ONC N/A
- Average True Range (ATR)
- CSGP 1.41
- ONC 0.00
- MACD
- CSGP -0.15
- ONC 0.00
- Stochastic Oscillator
- CSGP 32.54
- ONC 0.00
About CSGP CoStar Group Inc.
CoStar Group is a leading provider of commercial real estate data and marketplace listing platforms. Its data offering contains in-depth analytical information on over 5 million commercial real estate properties related to various subsectors including office, retail, hotels, multifamily, healthcare, industrial, self-storage, and data centers. It operates many flagship brands such as CoStar Suite, LoopNet, Apartments.com, BizBuySell, and Lands of America, with more than 80% of its revenue classified as subscription-based. The company recently expanded its presence in Canada, the United Kingdom, Spain, and France.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.